

Amendments to the Informal Sequence Listing:

Please replace the paragraph beginning at page 14, line 1, with the following amended paragraph:

**SEQ. ID NO: 21. Amino acid sequence of β -1,4-GalNAc transferase from *C. jejuni*
~~0:1~~ 0:10.**

Please replace the second paragraph beginning at page 14, line 1, with the following amended paragraph:

**SEQ. ID NO: 22. Nucleotide sequence of β -1,4-GalNAc transferase from *C. jejuni*
~~0:1~~ 0:36.**

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 52, at the end of the application.

In addition, in order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit that the computer-readable form in the instant application is identical with that filed in Application No. 10/303,128, filed November 21, 2002, a Divisional of 09/816,028, filed March 21, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/816,028 (mailed to the PTO on September 6, 2001) as the computer-readable form for the instant application. A paper copy of the last filed Sequence Listing from Application No. 09/816,028 is submitted herewith. The information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

The amendments to the Informal Sequence Listing correct errors of a typographical nature made without deceptive intent. The first corrects the serotype number of C. jejuni of SEQ ID NO:21 from O:1 to O:10 to conform to the nucleotide sequence immediately preceeding it, SEQ ID NO:20, and from which it is translated. The second amendment deletes "O:1" from the correct serotype, "O:36", for the nucleotide sequence for SEQ ID NO:22, whose translation product in SEQ ID NO:23 may be found immediately following, with the correct serotype.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. The information contained in the computer readable form of Application No. 09/816,028 was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy, a copy of which is enclosed for the convenience of the Examiner. This amendment contains no new matter.